Page last updated: 2024-11-08

aminoflavone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aminoflavone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID389710
CHEMBL ID62006
SCHEMBL ID2411480
MeSH IDM0370428

Synonyms (19)

Synonym
5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl-4h-chromen-4-one
nsc-686288
4h-1-benzopyran-4-one,8-difluoro-7-methyl-
NSC686288 ,
NCI60_031035
NCIMECH_000858
165179-35-1
aminoflavone
CHEMBL62006
5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methylchromen-4-one
5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl-4h-1-benzopyran-4-one
CCG-35825
2exs38428u ,
4h-1-benzopyran-4-one, 5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl-
unii-2exs38428u
RTUZVPPGTJRELI-UHFFFAOYSA-N
SCHEMBL2411480
DTXSID50167854
Q27254640

Research Excerpts

Overview

Aminoflavone (AF) acts as a ligand of the aryl hydrocarbon receptor (AhR) It is a promising therapeutic agent for breast cancer due to its unique mechanism of action.

ExcerptReferenceRelevance
"Aminoflavone (AF) acts as a ligand of the aryl hydrocarbon receptor (AhR). "( Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor.
Burger, A; Li, J; Polin, L; Shelton, P; Stark, K; Wu, J, 2013
)
2.04
"Aminoflavone is a unique DNA damaging agent currently undergoing phase I evaluation in a prodrug form (AFP464). "( Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
Ames, MM; Goetz, MP; Kuffel, MJ; Reinicke, KE, 2010
)
2.08
"Aminoflavone is a promising therapeutic agent for breast cancer due to its unique mechanism of action compared to commonly used drugs. "( Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
Ames, MM; Goetz, MP; Kuffel, MJ; Reinicke, KE, 2010
)
2.08
"Aminoflavone (AF) is an anticancer drug in early clinical trials, and its antiproliferative activity involves the induction of DNA-protein cross-links. "( Cytokeratin-RNA cross-linking mediated by the antitumor aminoflavone, 5-amino-2,3-fluorophenyl-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one.
Meng, LH; Meng, Z; Miao, ZH; Pommier, Y; Veenstra, TD, 2008
)
2.03

Effects

ExcerptReferenceRelevance
"Aminoflavone has a unique activity profile in the NCI 60 cell lines (COMPARE analysis; http://www.dtp.nci.nih.gov/docs/dtp_search.html), and exhibits potent cellular and animal antitumor activity."( DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells.
Antony, S; Kohlhagen, G; Liao, ZY; Meng, LH; Pommier, Y; Sausville, E, 2005
)
1.27
"Aminoflavone has a unique activity profile in the NCI 60 cell lines (COMPARE analysis; http://www.dtp.nci.nih.gov/docs/dtp_search.html), and exhibits potent cellular and animal antitumor activity."( DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells.
Antony, S; Kohlhagen, G; Liao, ZY; Meng, LH; Pommier, Y; Sausville, E, 2005
)
1.27

Treatment

ExcerptReferenceRelevance
"Aminoflavone treatment causes a translocation of the AhR from the cytoplasm to the nucleus with subsequent formation of AhR-XRE protein DNA complexes."( Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.
Alley, MC; Boswell, J; Ciolino, HP; Hollingshead, M; Hose, C; Kenney, S; Loaiza-Pérez, AI; Sausville, EA; Trepel, JB; Vistica, DT; Yeh, GC, 2004
)
1.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID121547Ratio of tumor growth rate of the drug-treated group relative to that of the control group at a dose of 6.3 mg/kg1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Structure-activity relationships of the 7-substituents of 5,4'-diamino-6,8,3'-trifluoroflavone, a potent antitumor agent.
AID103910In vitro cytotoxicity against MCF-7 cell lines, treated for 3 days then uptake of neutral red dye was measured1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Structure-activity relationships of the 7-substituents of 5,4'-diamino-6,8,3'-trifluoroflavone, a potent antitumor agent.
AID121542Ratio of tumor growth rate of the drug-treated group relative to that of the control group at a dose of 12.5 mg/kg1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Structure-activity relationships of the 7-substituents of 5,4'-diamino-6,8,3'-trifluoroflavone, a potent antitumor agent.
AID87594In vitro cytotoxicity against HeLa S3 cell lines, treated for 3 days then uptake of neutral red dye was measured1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Structure-activity relationships of the 7-substituents of 5,4'-diamino-6,8,3'-trifluoroflavone, a potent antitumor agent.
AID110267Compound was tested for percentage Body weight change in vivo against MCF-7 cells implanted into Nude Mice, Dosage 6.3(mg/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Structure-activity relationships of the 7-substituents of 5,4'-diamino-6,8,3'-trifluoroflavone, a potent antitumor agent.
AID110142Compound was tested for percentage Body weight change in vivo against MCF-7 cells implanted into Nude Mice, Dosage 12.5(mg/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Structure-activity relationships of the 7-substituents of 5,4'-diamino-6,8,3'-trifluoroflavone, a potent antitumor agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (2.63)18.2507
2000's11 (28.95)29.6817
2010's18 (47.37)24.3611
2020's8 (21.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.16 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index5.26 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]